DaxibotulinumtoxinA
Phase 3Small molecule
DaxibotulinumtoxinA is one of 39 small molecule programs targeting Migraine. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
102 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Triptans
PfizerPhase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
DaxibotulinumtoxinA
RRevance Therapeutics, Inc.
Phase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spasmodic Dysphonia1 trial
Cervical Dystonia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DaxibotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRevance Therapeutics, Inc.